Sugi Predict

Sugi Predict / Compounds / SCHEMBL443424

SCHEMBL443424

SCHEMBL443424

CC1(C)OB(c2c(F)cc(N)cc2F)OC1(C)C

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LPL P06858 5/20 0.39
▸ LIPG Q9Y5X9 5/20 0.39
▸ P2RX7 Q99572 1/20 0.32
▸ CA1 P00915 3/20 0.31
▸ CA2 P00918 3/20 0.31
▸ CA9 Q16790 3/20 0.31
▸ CA12 O43570 1/20 0.31
▸ CA3 P07451 1/20 0.31
▸ CA4 P22748 1/20 0.31
▸ CA6 P23280 1/20 0.31
▸ CA5A P35218 1/20 0.31
▸ CA7 P43166 1/20 0.31
▸ CA14 Q9ULX7 1/20 0.31
▸ CA5B Q9Y2D0 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ EGFR P00533 1/20 0.30
▸ F11 P03951 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21271970 0.85 EGFR (0.35) LPLLIPGMAPK1EGFR
SCHEMBL25418201 0.83 LPL (0.46) LPLLIPGP2RX7MAPK1
SCHEMBL327717 0.82 LPL (0.40) LPLLIPGP2RX7MAPK1
SCHEMBL29746620 0.81 LPL (0.30) LPLLIPG
SCHEMBL19950353 0.81 LPL (0.30) LPLLIPG
SCHEMBL10269418 0.80 LPL (0.39) LPLLIPGP2RX7CA1CA2
SCHEMBL29276139 0.80 LPL (0.39) LPLLIPGP2RX7MAPK1EGFR
SCHEMBL13429482 0.80 LPL (0.39) LPLLIPGP2RX7MAPK1
SCHEMBL23830131 0.79 LPL (0.40) LPLLIPGP2RX7
SCHEMBL21524518 0.79 LPL (0.36) LPLLIPGP2RX7F11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600728-B2 Interleukin-17 inhibitors NOVARTIS AG (CH) 2026-04-14 — — US disclosed
EP-3941919-B1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH INC (US) 2025-12-24 — — EP disclosed
US-12384778-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2025-08-12 — — US disclosed
US-12344603-B2 Pyrido-pyrimidinone and pteridinone compounds and methods of use GENENTECH, INC. (US) 2025-07-01 — — US disclosed
US-12091413-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2024-09-17 — — US disclosed
US-20240287059-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2024-08-29 — — US disclosed
EP-4146348-B1 INHIBITORS OF NEK7 KINASE HALIA THERAPEUTICS INC (US) 2024-07-03 — — EP disclosed
US-20230416259-A1 INHIBITORS OF NEK7 KINASE HALIA THERAPEUTICS INC (US) 2023-12-28 — — US disclosed
US-20230391782-A1 INTERLEUKIN-17 INHIBITORS NOVARTIS AG (CH) 2023-12-07 — — US disclosed
US-11795166-B2 Pyrazolopyridine compounds and uses thereof INCYTE CORPORATION (US) 2023-10-24 — — US disclosed
US-20180072741-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF INCYTE CORPORATION 2018-03-15 — — US disclosed
WO-2018049152-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER INCYTE CORPORATION (US) 2018-03-15 — — WO disclosed
WO-2015161011-A1 BENZAMIDE CGRP RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2015-10-22 — — WO disclosed
EP-2406258-B1 PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS CELLZOME LTD (GB) 2014-12-03 — — EP disclosed
US-20140296234-A1 PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS CELLZOME LIMITED 2014-10-02 — — US disclosed
US-8785457-B2 Pyrimidine derivatives as mTOR inhibitors CELLZOME LIMITED (GB) 2014-07-22 — — US disclosed
EP-2391602-B1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2013-12-04 — — EP disclosed
US-20120065202-A1 PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS CELLZOME LIMITED (GB) 2012-03-15 — — US disclosed
EP-2406258-A1 PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS Cellzome Limited (GB) 2012-01-18 — — EP disclosed
WO-2010103094-A1 PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS CELLZOME LIMITED (GB) 2010-09-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391782-A1 INTERLEUKIN-17 INHIBITORS IL17A, IL2, IL18 LPL 3575/4885LIPG 2444/4885P2RX7 159/4885
US-12384778-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 LPL 1774/4885LIPG 2028/4885P2RX7 1421/4885
US-11795166-B2 Pyrazolopyridine compounds and uses thereof PDXK, PCK1, PGK1 LPL 1774/4885LIPG 2028/4885P2RX7 1421/4885
US-12091413-B2 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 LPL 4300/4885LIPG 3916/4885P2RX7 88/4885
US-20120065202-A1 PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR LPL 4498/4885LIPG 4309/4885P2RX7 94/4885
US-20140296234-A1 PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS MTOR, RICTOR, RPTOR LPL 4498/4885LIPG 4309/4885P2RX7 94/4885
US-20180072741-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PDK2 LPL 1551/4885LIPG 1998/4885P2RX7 1893/4885
US-20230416259-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 LPL 4300/4885LIPG 3916/4885P2RX7 88/4885
US-20240287059-A1 PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF PDXK, PCK1, PGK1 LPL 1774/4885LIPG 2028/4885P2RX7 1421/4885
US-12344603-B2 Pyrido-pyrimidinone and pteridinone compounds and methods of use TYMP, TYMS, DPYD LPL 4642/4885LIPG 4807/4885P2RX7 589/4885
US-12600728-B2 Interleukin-17 inhibitors IL17A, IL2, IL1B LPL 4001/4885LIPG 4589/4885P2RX7 92/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.